Panoramic Capital LLC bought a new position in shares of Pulse Biosciences, Inc. (NASDAQ:PLSE - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 48,571 shares of the company's stock, valued at approximately $846,000. Panoramic Capital LLC owned approximately 0.08% of Pulse Biosciences at the end of the most recent reporting period.
Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Tower Research Capital LLC TRC grew its position in Pulse Biosciences by 98.1% in the fourth quarter. Tower Research Capital LLC TRC now owns 1,692 shares of the company's stock worth $29,000 after buying an additional 838 shares during the last quarter. KLP Kapitalforvaltning AS purchased a new position in Pulse Biosciences during the 4th quarter worth approximately $44,000. Caisse Des Depots ET Consignations purchased a new position in Pulse Biosciences during the 4th quarter worth approximately $95,000. Farther Finance Advisors LLC grew its position in Pulse Biosciences by 44.4% during the 4th quarter. Farther Finance Advisors LLC now owns 7,220 shares of the company's stock worth $126,000 after purchasing an additional 2,220 shares in the last quarter. Finally, SG Americas Securities LLC purchased a new position in Pulse Biosciences during the 4th quarter worth approximately $193,000. Institutional investors own 76.95% of the company's stock.
Pulse Biosciences Trading Down 0.6%
Shares of Pulse Biosciences stock traded down $0.10 on Monday, hitting $17.09. 22,974 shares of the company traded hands, compared to its average volume of 197,080. The company has a 50-day moving average price of $16.57 and a 200 day moving average price of $17.99. Pulse Biosciences, Inc. has a 12-month low of $7.61 and a 12-month high of $25.00.
Pulse Biosciences (NASDAQ:PLSE - Get Free Report) last posted its quarterly earnings results on Thursday, May 8th. The company reported ($0.25) EPS for the quarter.
Wall Street Analysts Forecast Growth
Separately, StockNews.com upgraded shares of Pulse Biosciences to a "sell" rating in a research report on Monday, March 31st.
Check Out Our Latest Report on PLSE
About Pulse Biosciences
(
Free Report)
Pulse Biosciences, Inc operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.
Further Reading
Before you consider Pulse Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pulse Biosciences wasn't on the list.
While Pulse Biosciences currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
